Product Description
Mechanisms of Action: PBP Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | India
Approved Indications: None
Known Adverse Events: None
Company: Replidyne
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pneumonia, Bacterial|Bronchitis, Chronic|Respiratory Tract Infections|Pneumonia
Phase 2: Pneumonia, Bacterial|Tuberculosis, Pulmonary|Otitis Media
Phase 1: Tuberculosis|Mycobacterium Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20233579 | N/A |
Completed |
Healthy Volunteers |
2024-01-22 |
|
| CTR20232271 | N/A |
Completed |
Skin Ulcer|Keratitis|Otitis Media|Mastitis|Inflammation|Pyelonephritis|Otitis Externa|Corneal Ulcer|Bronchitis, Chronic|Lung Abscess|Lymphadenitis|Dacryocystitis|Pneumonia|Tonsillitis|Pharyngitis|Burns Unspecified|Chronic Periodontitis|Lymphangitis|Prostatitis|Sinusitis|Orchitis |
2023-08-29 |
|
| CTR20223323 | N/A |
Completed |
Influenza, Human|Pneumonia |
2023-03-08 |
|
| CTR20222096 | N/A |
Completed |
Otitis Externa|Inflammation|Osteoma|Pyelonephritis|Prostatitis|Haemophilus Infections|Pneumonia|Burns Unspecified|Enterobacteriaceae Infections|Pharyngitis|Proteus Infections|Scarlet Fever|Mastitis|Lymphangitis|Dacryocystitis|Bronchitis, Chronic|Uterine Diseases|Whooping Cough|Lymphadenitis|Skin Ulcer|Epididymitis|Lung Abscess|Tonsillitis|Sinusitis|Chronic Cough|Skin Diseases, Infectious|Klebsiella Infections|Influenza, Human|Otitis Media|Pericoronitis|Corneal Ulcer|Chronic Periodontitis|Escherichia coli Infections |
2022-10-31 |